Distance traveled and cross-state commuting to opioid treatment programs in the United States
about
Spatial accessibility of drug treatment facilities and the effects on locus of control, drug use, and service use among heroin-injecting Mexican American men.A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entryA randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.Methadone treatment providers' views of drug court policy and practice: a case study of New York StatePatterns, determinants and barriers of health and social service utilization among young urban crack users in Brazil.Characterizing opioid withdrawal during double-blind buprenorphine detoxification.Bridging waitlist delays with interim buprenorphine treatment: initial feasibility.Interim treatment: Bridging delays to opioid treatment access.Participation dynamics of a cohort of drug users in a low-threshold methadone treatment programme.Racial/Ethnic Differences in Prevalence Trends for Heroin use and Non-Medical use of Prescription Opioids Among Entrants to Opioid Treatment Programs, 2005-2016.Racial and ethnic differences in opioid agonist treatment for opioid use disorder in a U.S. national sample.Rural and Appalachian Disparities in Neonatal Abstinence Syndrome Incidence and Access to Opioid Abuse Treatment.Vermont Hub-and-Spoke Model of Care for Opioid Use Disorder: Development, Implementation, and Impact.Opioid Overdose Experience, Risk Behaviors, and Knowledge in Drug Users from a Rural versus an Urban Setting.Disparities in the Treatment of Substance Use Disorders: Does Where You Live Matter?MySafeRx: a mobile technology platform integrating motivational coaching, adherence monitoring, and electronic pill dispensing for enhancing buprenorphine/naloxone adherence during opioid use disorder treatment: a pilot study
P2860
Q33786562-35CE47B3-D02A-4C0A-8731-F82E125890E6Q34030894-011DF852-1477-406F-B72D-929E2E3E0AE8Q34040286-F57EA902-C459-489E-ACF7-CDD044C64CDFQ34250149-0BD27B7A-ED49-4777-A2AB-E1EC62F0549AQ35076908-74000BA9-9F93-41DB-9A57-FC5D27B7C13FQ35660989-7AC0A8C1-D6EA-4AD9-9EE9-76E815159785Q36021346-9411F72E-7D20-40A6-A9E2-9C6377432684Q36117597-CD03BA2E-638E-4C3E-B1C7-B1BCF05E2452Q36169002-6F632B7D-B810-4627-832E-AE1212EF00DCQ38602295-13CD7098-6F1F-4F7F-8BDE-4C9A8CDE342BQ38673634-15F0E2A1-818C-4421-BDA1-72775C099DFCQ38689763-E9B929D0-9A2B-49F9-839D-C12EE7EA42C5Q38734667-FBD15385-8390-49E2-9C8E-73E37F9AB6CCQ38817326-C8E83383-683D-46A6-A251-50AA1782DF86Q50050738-2F15D740-7CDE-418D-B057-E468ACFE9A17Q58700874-635C732D-035E-4298-98B5-F4010EAEC51C
P2860
Distance traveled and cross-state commuting to opioid treatment programs in the United States
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Distance traveled and cross-st ...... programs in the United States
@ast
Distance traveled and cross-st ...... programs in the United States
@en
type
label
Distance traveled and cross-st ...... programs in the United States
@ast
Distance traveled and cross-st ...... programs in the United States
@en
prefLabel
Distance traveled and cross-st ...... programs in the United States
@ast
Distance traveled and cross-st ...... programs in the United States
@en
P2093
P2860
P356
P1476
Distance traveled and cross-st ...... programs in the United States
@en
P2093
Andrew Rosenblum
Barbara Tempalski
Charles M Cleland
Chunki Fong
Deborah J Kayman
Mark Parrino
P2860
P304
P356
10.1155/2011/948789
P577
2011-07-06T00:00:00Z